Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Exp Clin Endocrinol Diabetes ; 130(11): 714-722, 2022 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-36075228

RESUMEN

PURPOSE: To investigate the clinical characteristics and associated factors of colonic polyps in patients with acromegaly. METHODS: Clinical characteristics and colonoscopy findings of 86 acromegaly patients who received treatment were retrospectively reviewed, and colonoscopy findings and the correlation with growth hormone (GH)-secreting pituitary adenoma (GHPA) volume and hormonal/metabolic levels were analyzed. RESULTS: The prevalence of colonic polyps in acromegaly patients was 40.7% and increased significantly with advanced age, especially in those ≥50 years. Multiple polyps (62.8%) and colonic polyps in the left colon (54.2%) were detected more frequently. Compared to acromegaly patients without polyps, those with polyps displayed higher insulin-like growth factor-1 × upper limit of normal (IGF-1×ULN) levels (P=0.03). IGF-1 levels and GHPA volumes in patients with polyps showed increasing trends, although the differences were not significant. GH levels were higher in patients with polyps of diameter ≤5 mm than those with polyps of diameter >5 mm (P=0.031). The univariate and multivariate logistic regression analysis revealed that GHPA volumes (OR: 1.09, 95% CI: 1.01-1.20; P=0.039) and IGF-1×ULN Q2 levels (OR: 6.51, 95% CI: 1.20-44.60; P=0.038) were independent factors for predicting the risk of colonic polyp occurrence in acromegaly patients. A nomogram was prepared to evaluate the risk of colonic polyps in acromegaly patients. CONCLUSION: The acromegalic patients are a population with a high prevalence of colonic polyps. GHPA volumes and IGF-1×ULN levels may be predictors of colonic polyp occurrence.


Asunto(s)
Acromegalia , Adenoma , Pólipos del Colon , Adenoma Hipofisario Secretor de Hormona del Crecimiento , Humanos , Persona de Mediana Edad , Pólipos del Colon/epidemiología , Acromegalia/complicaciones , Acromegalia/epidemiología , Factor I del Crecimiento Similar a la Insulina/análisis , Estudios Retrospectivos , Adenoma/complicaciones , Adenoma/epidemiología
2.
Neurochem Res ; 42(2): 360-374, 2017 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-27743286

RESUMEN

Temporal lobe epilepsy (TLE) is one of the most refractory types of adult epilepsy, and treatment options remain unsatisfactory. Gastrodin (GAS), a phenolic glucoside used in Chinese herbal medicine and derived from Gastrodia elata Blume, has been shown to have remarkable anticonvulsant effects on various models of epilepsy in vivo. However, the mechanisms of GAS as an anticonvulsant drug remain to be established. By utilizing a combination of behavioral surveys, immunofluorescence and electrophysiological recordings, the present study characterized the anticonvulsant effect of GAS in a pilocarpine-induced status epilepticus (SE) rat model of TLE and explored the underlying cellular mechanisms. We found that GAS pretreatment effectively reduced the severity of SE in the acute phase of TLE. Moreover, GAS protected medial entorhinal cortex (mEC) layer III neurons from neuronal death and terminated the SE-induced bursting discharge of mEC layer II neurons from SE-experienced rats. Furthermore, the current study revealed that GAS prevented the pilocarpine-induced enhancement of Nav1.6 currents (persistent (INaP) and resurgent (INaR) currents), which were reported to play a critical role in the generation of bursting spikes. Consistent with this result, GAS treatment reversed the expression of Nav1.6 protein in SE-experienced EC neurons. These results suggest that the inhibition of Nav1.6 sodium currents may be the underlying mechanism of GAS's anticonvulsant properties.


Asunto(s)
Alcoholes Bencílicos/uso terapéutico , Epilepsia del Lóbulo Temporal/tratamiento farmacológico , Glucósidos/uso terapéutico , Canal de Sodio Activado por Voltaje NAV1.6/fisiología , Pilocarpina/toxicidad , Bloqueadores de los Canales de Sodio/uso terapéutico , Estado Epiléptico/tratamiento farmacológico , Animales , Alcoholes Bencílicos/farmacología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Epilepsia del Lóbulo Temporal/fisiopatología , Glucósidos/farmacología , Masculino , Ratas , Ratas Sprague-Dawley , Índice de Severidad de la Enfermedad , Bloqueadores de los Canales de Sodio/farmacología , Estado Epiléptico/inducido químicamente , Estado Epiléptico/fisiopatología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...